Get started
Author

Shoba Ravichandran

Observed name: Ravichandran, Shoba
OpenAlex ID: A5111310614
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
2009 · Ralph A. DeFronzo, Miguel N. Hissa, et al. · Diabetes Care · 417
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
2023 · Alexa B Kimball, Gregor B E Jemec, et al. · The Lancet · 338
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
2017 · André Lacroix, Feng Gu, et al. · The Lancet Diabetes & Endocrinology · 162
PDF
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease
2020 · John Newell-Price, Rosario Pivonello, et al. · European Journal of Endocrinology · 61
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
2011 · Antonio R Chacra, Gerry H Tan, et al. · Diabetes and Vascular Disease Research · 61
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
2020 · Mônica R Gadelha, Feng Gu, et al. · Endocrine Connections · 54
PDF
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials
2024 · Christos C Zouboulis, Thierry Passeron, et al. · British Journal of Dermatology · 33
PDF
Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin
2010 · Kaj Stenlöf, Itamar Raz, et al. · Current Medical Research and Opinion · 27
Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
2017 · James Yao, Jennifer A Chan, et al. · OncoTargets and Therapy · 19
PDF
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial
2024 · Alexa B Kimball, Falk G Bechara, et al. · British Journal of Dermatology · 18
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
2019 · Xiting Cao, Derek Tang, et al. · Clinical Genitourinary Cancer · 17
Efficacy and Safety of Saxagliptin Combination Therapy in US Patients with Type 2 Diabetes
2011 · Chetan Karyekar, Mark Donovan, et al. · Postgraduate Medicine · 17
Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with type 2 diabetes
2009 · Ralph A. DeFronzo, Miguel Nasser Hissa, et al. · ResearchOnline - JCU (James Cook University) · 17
PDF
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System ( IHS4 ): A post hoc analysis of the SUNSHINE and SUNRISE trials
2024 · Christos C. Zouboulis, Athanassios Kyrgidis, et al. · Journal of the European Academy of Dermatology and Venereology · 15
PDF
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab
2023 · Christos C. Zouboulis, Errol P. Prens, et al. · Journal of the European Academy of Dermatology and Venereology · 14
New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials
2024 · Anna Passera, Elisa Muscianisi, et al. · Journal of the European Academy of Dermatology and Venereology · 9
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials
2023 · Xiaoling Wei, Anna Passera, et al. · Journal of the American Academy of Dermatology · 8
PDF
Revisiting the SUNSHINE and SUNRISE trials
2024 · Alexa B Kimball, Shoba Ravichandran · The Lancet · 7
Metformin-based oral antidiabetic therapy proved effective in hyperglycaemia associated with pasireotide in patients with acromegaly
2015 · Anna Maria Colao, Feng Gu, et al. · Endocrine Abstracts · 6
PDF
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours
2020 · Darcy B. Pooler, Dylan B. Ness, et al. · British Journal of Clinical Pharmacology · 5
Saxagliptin added to a thiazolidinedione, metformin or a sulphonylurea improves glycaemic control in patients with inadequately controlled type 2 diabetes mellitus
2009 · Pierre Maheux, Elsie Allen, et al. · 11th European Congress of Endocrinology · 4
Long‐term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236‐week, Phase 3 trial results
2025 · Andrzej Kaszuba, Philemon Papanastasiou, et al. · Journal of the European Academy of Dermatology and Venereology · 3
PDF
Predictors of response to long-acting pasireotide in patients with Cushing's disease during a Phase III study
2018 · Przemyslaw Witek, Beverly M K Biller, et al. · Endocrine Abstracts · 3
Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial
2025 · Kulli Kingo, Philemon Papanastasiou, et al. · Pediatric Drugs · 2
PDF
Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies
2025 · Afsaneh Alavi, Ziad Reguiai, et al. · International Journal of Dermatology · 2
PDF
Works count: 42
Citation count: 1,329
H-index: 14
I10-index: 15
Year
Topic
Type